TP53 and B-cell chronic lymphocytic leukemia: In the Phase 3 GAIA (CLL13) clinical trial,58 patients with CLL who were fit and had no TP53 gene abnormalities were randomized in a 1:1:1 ratio to receive six cycles of chemotherapy: one to six cycles of chemoimmunotherapy (fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab) or 12 cycles of venetoclax-rituximab, venetoclax-obinutuzumab or venetoclax-obinutuzumab-ibrutinib.